Liminatus Pharma, Inc. financial data

Symbol
LIMN, LIMNW on Nasdaq
Location
La Palma, CA
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -77.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.1M shares
Common Stock, Shares, Outstanding 27.1M shares
Common Stock, Value, Issued 2.71K USD
Weighted Average Number of Shares Outstanding, Basic 27M shares +54.3%
Weighted Average Number of Shares Outstanding, Diluted 27M shares +54.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 701K USD +277%
Operating Income (Loss) -701K USD -29.1%
Nonoperating Income (Expense) -1.12M USD -1827%
Net Income (Loss) Attributable to Parent -1.82M USD -203%
Earnings Per Share, Basic -0.07 USD/shares -133%
Earnings Per Share, Diluted -0.07 USD/shares -133%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.2M USD
Property, Plant and Equipment, Net 12.8K USD
Assets 1.34M USD
Liabilities, Current 2.86M USD
Liabilities 2.99M USD
Retained Earnings (Accumulated Deficit) -30.7M USD
Stockholders' Equity Attributable to Parent -1.65M USD +91.4%
Liabilities and Equity 1.34M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 27.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 29.1M USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares